Moreover, inhibitors of glycogen degradation metabolism regulated by PYGL has already been discovered like CP91149, CP320626 and Flavoperidol, but neither of them has been applied in HNSCC treatment [51–54], implicating a great potential of PYGL targeting therapy. This evidence concerns the gene PYGL and head and neck squamous cell carcinoma.